VALSARTAN (valsartan oral) by Rubicon Biotechnology is angiotensin 2 receptor antagonists [moa]. First approved in 2025.
Drug data last refreshed 18h ago
Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania
A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
Bioequivalence Study of Amlodipine/Valsartan 10/160 mg Film Coated Tablets
Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Worked on VALSARTAN at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.